A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
出版年份 2014 全文链接
标题
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 111, Issue 4, Pages 660-666
出版商
Springer Nature
发表日期
2014-06-25
DOI
10.1038/bjc.2014.356
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
- (2014) Valérie F. Cosson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- P-0111 * PERTUZUMAB, TRASTUZUMAB AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER: AN INTERNATIONAL PHASE III STUDY (JACOB)
- (2013) P. Hoff et al. ANNALS OF ONCOLOGY
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- The 5-Year Relative Survival Rate of Stomach Cancer in the USA, Europe and Japan
- (2013) T. Matsuda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?
- (2013) Koji Chiba et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients
- (2013) Min Zhu et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study
- (2013) Roberta De Angelis et al. LANCET ONCOLOGY
- Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010
- (2013) Kyu-Won Jung et al. Cancer Research and Treatment
- Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study
- (2013) Kyu-Won Jung et al. Cancer Research and Treatment
- Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Javier Cortés et al. JOURNAL OF CLINICAL ONCOLOGY
- The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
- (2012) Jun Yang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
- (2011) Manish Gupta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
- (2009) C. Jackson et al. ANNALS OF ONCOLOGY
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
- (2009) Xiu Li Zhang et al. WORLD JOURNAL OF SURGERY
- A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
- (2008) J. Albanell et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started